Vimarsana
Biggest News Aggregation in the World

Nasdaq Acrs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Acrs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Acrs Today - Breaking & Trending Today

FY2023 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Lifted by HC Wainwright - Vimarsana News

FY2023 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Lifted by HC Wainwright

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Analysts at HC Wainwright upped their FY2023 earnings estimates for Aclaris Therapeutics in a report released on Monday, January 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($1.65) per share for the year, up from their previous forecast of […]

Source: wkrb13.com
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to "Neutral" at HC Wainwright - Vimarsana News

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to "Neutral" at HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. A number of other equities research analysts also recently weighed in on the company. William Blair downgraded Aclaris Therapeutics from […]

Source: wkrb13.com
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Moderate Buy" from Analysts - Vimarsana News

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Moderate Buy" from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective […]

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Analysts - Vimarsana News

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average […]

Source: wkrb13.com
Aclaris Therapeutics' (ACRS) Neutral Rating Reiterated at Cantor Fitzgerald - Vimarsana News

Aclaris Therapeutics' (ACRS) Neutral Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a research report report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2023 earnings at ($1.57) EPS and FY2024 earnings at ($0.99) EPS. A number of other research firms have also recently weighed […]